Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of Pemphigus vulgaris

Clinical and Experimental Immunology

Volumn 162, Issue 3, 2010, Pages 543-549

  Mimouni, D ^a,c,d   Blank, M ^a,d   Payne, A S ^e   Anhalt, G J ^f   Avivi, C ^b   Barshack, I ^b,d   David, M ^c,d   Shoenfeld, Y ^a,d  

^a Department of Medicine B and Zabludowicz Center for Autoimmune Diseases ^*  (United States)

^b Institute of Pathology   (United States)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Autoimmunity; Desmoglein; IVIG; Pemphigus

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; IMMUNOGLOBULIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; AUTOANTIBODY; DESMOGLEIN 1; DESMOGLEIN 3; EPITOPE;

ACANTHOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FEMALE; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOPATHOLOGY; IN VITRO STUDY; INHIBITION KINETICS; LOW DRUG DOSE; MOUSE; NEWBORN; NONHUMAN; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PURIFICATION; SKIN; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PEMPHIGUS; PROTEIN ENGINEERING;

ACANTHOLYSIS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIBODIES; DESMOGLEIN 1; DESMOGLEIN 3; DISEASE MODELS, ANIMAL; EPITOPES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED C57BL; PEMPHIGUS; PROTEIN ENGINEERING; SINGLE-CHAIN ANTIBODIES; SKIN;

EID: 79952465992     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04265.x     Document Type: Article

References (57)

1. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306:1189-96.
2. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94:59-67.
3. Ishii K, Amagai M, Hall RP et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159:2010-17.
4. Mimouni D, Anhalt GJ. Pemphigus. Dermatol Ther 2002; 15:362-8.
5. Stanley JR. Pemphigus. In: Freedberg IM, Eisen AZ, Wolff K et al., eds. Fitzpatrick's dermatology in general medicine, 5th edn. New York: McGraw-Hill, 1999:654-66.
6. Vani J, Elluru S, Negi VS et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008; 7:440-4.
7. Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the content of the magic draft IVIg? Autoimmun Rev 2008; 7:435-9.
8. Krause I, Wu R, Sherer Y, Patanik M, Peter J, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations-a potential role for adjuvant in travenous immunoglobulin therapy in infectious diseases. Transfus Med 2002; 12:133-9.
9. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-55.
10. Sultan Y, Kazatchkine MD, Maissoneuve P, Nydegger UE. Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2:765-8.
11. Krause I, Blank M, Shoenfeld Y. Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. J Clin Immunol 1998; 18:52-60.
12. Evans MJ, Suenaga R, Abdou NI. Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin. J Clin Immunopathol 1991; 11:291-5.
13. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific IgG. J Immunol 1989; 143:4104-9.
14. Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991; 83:298-303.
15. Tandon N, Jayne DR, McGregor AM, Weetman AP. Analysis of anti-idiotypic antibodies against antimicrosomal antibodies in patients with thyroid autoimmunity. J Autoimmun 1992; 5:557-70.
16. Lundkvist I, van Doorn PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol 1993; 67:192-8.
17. Caccavo D, Vaccaro F, Ferri GM, Amoroso A, Bonomo L. Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun 1994; 7:537-48.
18. Mehta YS, Badakere SS. In-vitro inhibition of antiplatelet autoantibodies by intravenous immunoglobulins and Rh immunoglobulins. J Postgrad Med 1996; 42:46-9.
19. DeKeyser F, DeKeyser H, Kazatchkine MD, Rossi F, Dang H, Talal N. Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol 1996; 14:587-91.
20. Yuki N, Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci 1996; 139:160-2.
21. Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 2004; 24:107-14.
22. Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serological response. Lupus 1999; 8:705-12.
23. Terryberry JF, Shoenfeld Y, Sherer Y et al. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations. Immunol Invest 2000; 29:337-47.
24. Sherer Y, Wu R, Krause I, Peter JB, Shoenfeld Y. Antiphospholipid antibody levels in intravenous immunoglobulin (IVIG) preparations. Lupus 2001; 10:568-70.
25. Silvestris F, Cafforio P, Dammacco F. Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol 1994; 97:19-25.
26. Evans M, Abdou NI. In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin. Lupus 1993; 2:371-5.
27. Mimouni D, Blank M, Ashkenazi L et al. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 2005; 142:426-32.
28. Amagai M, Ikeda S, Shimizu H et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60:595-603.
29. Payne AS, Ishii K, Kacir S et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. J Clin Invest 2005; 115:888-99.
30. Payne AS, Siegel DL, Stanley JR. Targeting pemphigus autoantibodies through their heavy-chain variable region genes. J Invest Dermatol 2007; 127:1681-91.
31. Parham P. Preparation and purification of active fragments from mouse monoclonal antibodies. In: Herzenberg LA, Weir DM, Blackwell C, eds. Handbook of experimental immunology, vol 2. Oxford: Blackwell Scientific Publications, 1994:14-35.
32. Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol 1996; 106:351-5.
33. Cheng SW, Kobayashi M, Tanikawa A, Kinoshita-Kuroda K, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147:261-5.
34. Rock B, Labib RS, Diaz LA. Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. J Clin Invest 1990; 85:296-9.
35. Anhalt GJ, Till GO, Diaz LA, Labib RS, Patel HP, Eaglstein NF. Defining the role of complement in experimental pemphigus vulgaris in mice. J Immunol 1986; 137:2835-40.
36. Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976; 67:254-60.
37. Hashimoto K, Shafran KM, Webber PS, Lazarus GS, Singer KH. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. J Exp Med 1983; 157:259-72.
38. Koch PJ, Mahoney MG, Ishikawa H et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997; 137:1091-102.
39. Shimizu A, Ishiko A, Ota T, Tsunoda K, Amagai M, Nishikawa T. IgG binds to desmoglein 3 in desmosomes and causes a desmosomal split without keratin retraction in a pemphigus mouse model. J Invest Dermatol 2004; 122:1145-53.
40. Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol 1999; 112:67-71.
41. Sato M, Aoyama Y, Kitajima Y. Assembly pathway of desmoglein 3 to desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as revealed by time-lapsed labeling immunoelectron microscopy. Lab Invest 2000; 80:1583-92.
42. Calkins CC, Setzer SV, Jennings JM et al. Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies. J Biol Chem 2006; 281:7623-34.
43. Shu E, Yamamoto Y, Sato-Nagai M, Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG reduces the desmoglein 3/desmocollin 3 ratio on the cell surface in cultured keratinocytes as revealed by double-staining immunoelectron microscopy. J Dermatol Sci 2005; 40:209-11.
44. Demlehner MP, Schäfer S, Grund C, Franke WW. Continual assembly of half-desmosomal structures in the absence of cell contacts and their frustrated endocytosis: a coordinated Sisyphus cycle. J Cell Biol 1995; 131:745-60.
45. Aoyama Y, Owada MK, Kitajima Y. A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur J Immunol 1999; 29:2233-40.
46. Caldelari R, de Bruin A, Baumann D et al. A central role for the armadillo protein plakoglobin in the autoimmune disease pemphigus vulgaris. J Cell Biol 2001; 153:823-34.
47. Berkowitz P, Hu P, Liu Z et al. Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization. J Biol Chem 2005; 280:23778-84.
48. Sánchez-Carpintero I, Espãa A, Pelacho B et al. In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol 2004; 151:565-70.
49. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138:1158-62.
50. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47:358-63.
51. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003; 13:377-81.
52. Herzog S, Schmidt E, Goebeler M, Brocker EB, Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84:48-52.
53. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med 2004; 10:17-18.
54. Blank M, Anafi L, Zandman-Goddard G et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007; 19:857-65.
55. Blank M, Nur I, Toub O, Maor A, Shoenfeld Y. Toward molecular targeting with specific intravenous immunoglobulin preparation. Clin Rev Allergy Immunol 2005; 29:213-17.
56. Shoenfeld Y, Rauova L, Gilburd B et al. Efficacy of IVIG affinity- purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14:1303-11.
57. Fuchs S, Feferman T, Meidler R et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol 2008; 194:89-96.